Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
19.02.2026 14:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts […]
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19.02.2026 12:00
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Adminis
FDA Accepts Regeneron's Garetosmab BLA For Priority Review For Treatment Of Adults With Fibrodysplasia Ossificans Progressiva
19.02.2026 08:11
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab
Ocular Therapeutix stock news: Why positive data led to a 25% drop
17.02.2026 13:30
Investing.com -- Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular degeneration (AMD). EyePoint (NASDAQ:EYPT) shares dropped 15%, while Regeneron Pharmaceuticals (NASDAQ:REGN) shares were flat.
Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes
17.02.2026 10:15
Ocular Therapeutix shares tumble after Axpaxli wet AMD trial data disappoints investors, despite meeting key Phase 3 goals.
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?
13.02.2026 14:57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]
Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
13.02.2026 09:23
Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.
The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL
11.02.2026 09:56
NVDA, AMZN and REGN headline Zacks' top stock reports, spotlighting AI growth, cloud momentum and oncology pipeline strength.
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook
08.02.2026 09:27
Sanofi (NASDAQ:SNY) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Sanofi SA (NASDAQ:SNY) reiterated plans to conduct a €1 billion share buyback in 2026. The buyback push comes as the company delivered a strong Q4 2025. Sanofi posted strong fourth-quarter results, driven by surging demand for its […]
Have originator medicines’ list prices started to drop in the US?
06.02.2026 14:26
According to the GlobalData service Price Intelligence (POLI) & HTA, more than 800 originator molecules still posted price hikes to their WACs and AWPs.
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
02.02.2026 12:00
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosingTARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on Februar
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines
31.01.2026 17:35
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% […]
Regeneron: Expect Double-Digit Growth In 2026
31.01.2026 08:33
Regeneron Pharmaceuticals, Inc. targets double-digit 2026 growth via Dupixent expansion and fewer Eylea headwinds. Check out why REGN stock is a buy.
Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell
30.01.2026 13:47
Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.
Sanofi touts strong new launch sales amid looming Dupixent patent expiry
30.01.2026 12:56
The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.
Regeneron beats quarterly profit estimates on Dupixent strength
30.01.2026 12:40
Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
30.01.2026 12:40
Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Regeneron: Q4 Earnings Snapshot
30.01.2026 11:47
The Tarrytown, New York-based company said it had net income of $7.86 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $11.44 per share. The results beat Wall Street expectations.
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025
30.01.2026 11:40
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was 6.9% above analysts’ consensus estimates.